Dear members,

Please find [here](https://www.bundesgesundheitsministerium.de/fileadmin/Dateien/3_Downloads/G/G20-Gesundheitsministertreffen/G20_Health_Ministers_Declaration_engl.pdf) the finalised declaration issued by the G20 Health Ministers (concerning Diagnostics only):

 *All relevant stakeholders, taking into account their respective capacities, need to be involved in preventing, preparing for and responding to current and future health crises, guided by the leadership of WHO. This includes recommended actions on a needs-based and disease burden basis, and to cooperate for making required medicines, diagnostics, vaccines and treatment available to the people in need.*

*15. Research and Development (R&D) are necessary for the timely availability and development of new and improved quality medicines, vaccines, diagnostics and medical equipment for containing emergencies. This requires mobilization of national and international research efforts and facilities, and norms and commitments to share data and samples, in accordance with national legislation, and public health benefits in an inclusive, timely and transparent manner. In addition, sustainable funding and effective international R&D coordination is needed.*

*We welcome and support new models for R&D preparedness including the “WHO R&D Blueprint”, the Global Research Collaboration for Infectious Disease Preparedness (GLOPID-R) and the “Coalition for Epidemic Preparedness Innovations (CEPI)”, which is developing new vaccines for epidemics. We underscore the importance that products emerging from such R&D efforts become accessible to all people in need. In regard to sample and data sharing, we recognize the importance of the WHO global influenza surveillance and response system and Pandemic Influenza Preparedness (PIP) framework, as well as the global initiative on sharing all influenza data.*

*28. The prudent use of antimicrobials in both human and animal health is of utmost importance to preserve the effectiveness of existing and new antibiotics for as long as possible. Medical examinations and the use of appropriate diagnostics support the prudent use of antimicrobials. We will raise awareness about the seriousness of AMR and of the negative consequences of inappropriate use of antimicrobials among both the general public and health professionals. We commit to participate in the development of the WHO Global Framework for Development and Stewardship to combat Antimicrobial Resistance. We will promote the development and support the implementation of antimicrobial stewardship programs to reduce inappropriate antibiotic consumption by humans within our countries and the requirement that treatment with antibiotics must be prescribed and dispensed by domestically certified health professionals. We support improving responsible antibiotic prescription practices in humans and promote access to antimicrobials as needed under appropriate medical supervision. We will foster the reduction of the inappropriate use of antibiotics through education, training of health professionals and the use of appropriate diagnostic tools.*

*30. We note with concern that the research and development (R&D) pipeline for developing new antimicrobial therapies against life-threatening and highly resistant organisms has been drying up and does not correspond to the global needs in light of growing antimicrobial resistance during past decades. We highlight the importance of fostering R&D for new antimicrobials, alternative therapies, vaccines and rapid-point-of care diagnostics, in particular for priority pathogens as identified by WHO and for tuberculosis.*

*We recognize the importance of reactivating the R&D pipeline through incentive mechanisms that avoid the reliance on high price/volume combinations. We also recognize the need to promote prudent and responsible use of antimicrobials. In the Hangzhou G20 Leaders’ Communiqué, G20 leaders called on the WHO, FAO, OIE and OECD to collectively report back in 2017. Their report ‘Tackling Antimicrobial Resistance, Ensuring Sustainable R&D’ will be considered by leaders when they meet on 7-8 July. In this context we support ongoing initiatives, examining push and pull mechanisms that take into account needs of all countries and stress the need for a better coordination of existing initiatives. Furthermore, we note the importance of affordable access to new and existing antimicrobial drugs, diagnostic tools, alternative therapies and vaccines of quality to all patients in need. We will preserve the widest possible therapeutic treatment options through avoiding removal of old antibiotics from the market and work for a sustainable solution to address this issue*

*32. We recognise drug-resistant tuberculosis as an important threat and therefore commit to address tuberculosis within interventions for AMR. We acknowledge the need to develop and promote access to new drugs, diagnostics and vaccines to tackle drug-resistant tuberculosis consistent with the WHO End TB Strategy. We recognize the importance of other relevant initiatives and plans, such as the STOP TB Partnership. We welcome the decision by Member States to hold a United Nations HighLevel Meeting on Tuberculosis in 2018 and the WHO Ministerial Conference on Ending TB in the Sustainable Development Era to be held in Moscow in November 2017.*

Please find below also the German Presidency of the G20 [press release](https://www.bundesgesundheitsministerium.de/en/ministry/g20-health-ministers-meeting.html) marking the outcome of the meeting.